y90 monoclonal antibody lym-1
mAbexperimentalADC
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2001 (NCT00008021)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- HLA class II histocompatibility antigen, DR alpha chainImmunity, passive
HLA-DRA immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 90-Yttrium
Oral
No
Parenteral
No
Topical
No
Also known as
- y90 monoclonal antibody lym-1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00009776 | Phase 1 | Mar 1, 2001 | University of California, Davis |
| NCT00008021 | Phase 1 | Feb 1, 2001 | University of California, Davis |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of California, Davis | Academic/Hospital | 2 | 2 | 1 | 2001 |
1 organizations
Page 1 / 1